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Abstract
Metastatic cancers commonly activate adaptive chemotherapy
resistance, attributed to both microenvironment-dependent
phenotypic plasticity and genetic characteristics of cancer cells.
However, the contribution of chemotherapy itself to the non-
genetic resistance mechanisms was long neglected. Using high-
grade serous ovarian cancer (HGSC) patient material and cell lines,
we describe here an unexpectedly robust cisplatin and carboplatin
chemotherapy-induced ERK1/2-RSK1/2-EphA2-GPRC5A signaling
switch associated with cancer cell intrinsic and acquired chemore-
sistance. Mechanistically, pharmacological inhibition or knock-
down of RSK1/2 prevented oncogenic EphA2-S897 phosphorylation
and EphA2-GPRC5A co-regulation, thereby facilitating a signaling
shift to the canonical tumor-suppressive tyrosine phosphorylation
and consequent downregulation of EphA2. In combination with
platinum, RSK inhibitors effectively sensitized even the most plat-
inum-resistant EphA2high, GPRC5Ahigh cells to the therapy-induced
apoptosis. In HGSC patient tumors, this orphan receptor GPRC5A
was expressed exclusively in cancer cells and associated with
chemotherapy resistance and poor survival. Our results reveal a
kinase signaling pathway uniquely activated by platinum to elicit
adaptive resistance. They further identify GPRC5A as a marker for
abysmal HGSC outcome and putative vulnerability of the chemo-
resistant cells to RSK1/2-EphA2-pS897 pathway inhibition.
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Introduction
Despite advances in anti-cancer treatments, majority of patients
with disseminated metastases eventually recur with an increasingly
therapy-resistant disease (Dagogo-Jack & Shaw, 2018). Both intrin-
sic and acquired drug resistance mechanisms contribute to tumor
heterogeneity and evolution of genetically resistant cancer clones
(McGranahan & Swanton, 2017; Dagogo-Jack & Shaw, 2018). Exten-
sive evidence also indicates that tumor microenvironment (TME)-
dependent phenotypic plasticity contributes to the therapy resis-
tance and recurrent growth (Fischer et al, 2015; Zheng et al, 2015;
Senthebane et al, 2017). Although chemotherapy-induced changes
in both the cancer cells and the TME have been linked to tumor
aggressiveness (Norouzi et al, 2018; Redfern et al, 2018), the effects
of chemotherapy itself on the non-genetic, adaptive signaling mech-
anisms activated in the treatment-escaping cancer cells remain
elusive.
To dynamically communicate within the TME, tumor cells utilize
cell surface receptors (Friedl & Alexander, 2011). The erythropoi-
etin-producing hepatocellular receptor A2 (EphA2) is a widely
expressed member of the largest receptor tyrosine kinase (RTK)
family, the Eph receptors. EphA2 signals in a context-dependent and
dual manner: (i) via ephrinA ligand-induced auto-phosphorylation
at the cytoplasmic tyrosine residues, which can occur in connection
with epithelial cell adhesion, and generally inhibits oncogenic
signaling; or (ii) by ligand-independent signaling, whereby EphA2 is
phosphorylated at cytoplasmic S897 residue, driving downstream
pro-tumorigenic signaling upon crosstalk with other RTKs and
signaling molecules (Gucciardo et al, 2014; Riedl & Pasquale, 2015;
Kania & Klein, 2016; Zhou & Sakurai, 2017).
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Reportedly, the kinases Akt, PKA, and p90 ribosomal S6 kinases
(RSK/p90-RSK/S6KA) can mediate tumor-promoting EphA2-S897
phosphorylation (Miao et al, 2009; Zhou et al, 2015; Barquilla et al,
2016). Among the RSK family, RSK1 and RSK2 support tumor
growth and survival, whereas RSK3 and RSK4 are frequently down-
regulated in aggressive cancers (Casalvieri et al, 2017). In the
context-dependent regulation, EphA2-pS897 signaling has been
linked to over-activation of EphA2, Src-kinase activation, and
EphA2 cleavage by matrix metalloproteinase MMP14/MT1-MMP
(Sugiyama et al, 2013; Koshikawa et al, 2015; Hamaoka et al,
2018). Through such oncogenic signaling crosstalk, EphA2 can alter
cell–cell contacts and extracellular matrix (ECM) adhesion or degra-
dation to promote anchorage-independence, invasion in collagen-
rich TME, drug resistance, and stem-like properties (Thaker et al,
2004; Lu et al, 2008; Sugiyama et al, 2013; Zhou & Sakurai, 2017;
Giorgio et al, 2018).
Ovarian cancer (OC) is the most lethal gynecologic malignancy
(Siegel et al, 2018). High-grade serous ovarian cancer (HGSC)
accounts for approximately 70% of diagnosed cases, majority of
which are in metastatic stages (Seidman et al, 2004; Kobel et al,
2010; Torre et al, 2018). Metastatic HGSC is associated with aggres-
sive dissemination in the abdominal cavity, which occurs via
detachment of OC cells from the primary tumor to the peritoneal
fluid, followed by accumulation of the metastatic cells and multicel-
lular aggregates in ascites (Kenny et al, 2007; Hjerpe et al, 2018).
Upon exposure to specific cues, OC cells adhere and grow as solid
metastatic lesions in peritoneal organs, including the fatty omentum
as the preferred site for invasion and induction of collagen-rich
desmoplastic TME (Kenny et al, 2007, 2011; Luo et al, 2016).
The relatively effective first-line therapy for HGSC patients is
debulking surgery coupled to platinum-based chemotherapy
(Marchetti et al, 2010). Despite initial treatment response, most
HGSCs recur, often as a repeatedly chemo-sensitive disease (Pfis-
terer & Ledermann, 2006; Armbruster et al, 2018). This indicates
that besides genetic changes and selection, more plastic resistance
mechanisms are activated upon the aggressive disease progression
(Friedl & Alexander, 2011). Targeting these mechanisms could
provide effective combinatorial treatments urgently needed to elimi-
nate also the chemotherapy-escaping OC (micro)metastases from
sustaining aggressive tumor evolution.
Frequently overexpressed in OC, EphA2 associates with high
tumor grade, advanced stage, and poor clinical outcome (Thaker
et al, 2004). It has been recognized as a putative target to block
HGSC progression, although currently developed molecular-targeted
therapies lack proof for specificity and efficacy (Landen et al,
2005b; Petty et al, 2018). In adhesion-dependent signaling, EphA2
cooperates with integrins, the transmembrane receptors that link
the ECM to cell cytoskeleton (Hamidi & Ivaska, 2018). Moreover,
the G-protein coupled receptor Class C, Group 5, Member A
(GPRC5A) has been identified as an interactor of EphA2 and b1-
integrin (Bulanova et al, 2017). While tumor-suppressive and onco-
genic functions have been reported for this orphan receptor, possi-
ble GPRC5A functions in OC remain unknown (Zhou & Rigoutsos,
2014).
Intrigued by our unexpected observation of platinum-induced
EphA2 upregulation in ex vivo 3D collagen cultures of HGSC patient
cells, we used relevant cell models and clinical tumor material
to understand the EphA2-GPRC5A pathway and its clinical
implications in OC. Our results uncover a robust platinum-induced
switch in EphA2 signaling duality via RSK activation, which phar-
macological reversal allowed elimination of the otherwise resistant
GPRC5A overexpressing cells.
Results
Cisplatin treatment leads to EphA2 upregulation in patient-
derived HGSC cells ex vivo
For investigating HGSC signaling and TME-dependent resistance to
platinum chemotherapy, we established ex vivo cultures from the
ascites of treatment-naı̈ve patients with metastatic disease (Table 1).
The fresh patient cells were plated to ascites-like culture growing
spontaneously as suspension cells and spheres, or embedded in 3D
collagen, which typifies the collagen-rich desmoplastic microenvi-
ronment around solid HGSC metastatic lesions (Kenny et al, 2007).
By immunofluorescence, these cells were 60–90% positive for the
nuclear HGSC marker PAX8 (Fig EV1A; Laury et al, 2010). Ex vivo
cell responses to cisplatin were variable with part of the patient
cultures showing treatment resistance particularly when embedded
in collagen (Fig EV1B). In such culture, cisplatin affected the cell
viability by increased apoptosis (Fig EV1C–E, cleaved caspase-3).
The cells grew in 3D collagen as colonies positive for cytokeratin
7 (CK7; epithelial HGSC marker; Lengyel, 2010), with or without
surrounding residual CK7, vimentin+ mesenchymal cells (Fig 1A;
see OCKI_p01 and OCKI_p02, respectively). The CK7+ cell morphol-
ogy ranged from compact sphere-forming cells, prominent in
cultures OCKI_p01 and OCKI_p02, to round cells in looser grape-like
colonies in relatively resistant cultures OCKI_p03 and OCKI_p06
(Fig 1A). Considering the rounded collagen invasive phenotype of
OCKI_p03 and OCKI_p06 cells, resembling the reported EphA2-
dependent breast cancer cell phenotypes (Sugiyama et al, 2013),
and EphA2 association with OC clinical outcome (Thaker et al,
2004), we analyzed EphA2 in these ex vivo cultures by immunofluo-
rescence. Significantly, cisplatin treatment led to over twofold
increased EphA2 intensity in the treatment-escaping OCKI_p01,
OCKI_p03, and OCKI_p06, while OCKI_p02 cells were positive for
EphA2 also prior treatment (Fig 1B and C; OCKI_p01: 3.8  0.2,
OCKI_p03: 3.5  0.2, and OCKI_p06: 2.0  0.1-fold increase,
P ≤ 0.008).
Platinum induces an oncogenic feedback response via EphA2
tyrosine–serine phosphorylation switch in OC cell lines and
patient-derived cells
The context-dependent EphA2 signaling can occur via ligand-
induced tyrosine auto-phosphorylation, generally considered tumor-
suppressive, or via oncogenic, ligand-independent phosphorylation
of the S897 residue (Gucciardo et al, 2014; Zhou & Sakurai, 2017).
To examine whether platinum chemotherapy affects this EphA2
signaling duality, OVCAR3, OVCAR4, and OVCAR8 cells were first
treated with up to 20 lM cisplatin for 72 h (see Appendix Fig S1A
and B for cell characterization). In all these human OC cell lines,
EphA2 was constitutively expressed and increased after platinum
treatment (Fig 2A). The ligand-independent EphA2-pS897 was like-
wise enhanced. The tumor-suppressive EphA2-pY588 was increased
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in OVCAR3 and to a less extent in OVCAR4, but was low in OVCAR8
with and without cisplatin (Fig 2A–C). Notably, the pS897/pY588
ratio increased in all three cell models compared to untreated
controls (Fig 2B; OVCAR3: 5 lM cisplatin 2.7  0.6, OVCAR4:
10 lM cisplatin 4.2  0.5, and OVCAR8: 20 lM cisplatin 3.5  0.1-
fold increase, P ≤ 0.047). Moreover, OVCAR3 and OVCAR4 with
low pS897/pY588 ratio prior treatment were sensitive to cisplatin,
whereas platinum-resistant OVCAR8 had constitutive oncogenic
EphA2-pS897 dominance (Fig 2C and D; cell viability at 20 lM
cisplatin: OVCAR3 24.3  10.7% and OVCAR4 20.9  6.8% vs.
OVCAR8 84.7  3.3%, P < 0.001).
Patient-derived HGSC cultures likewise expressed EphA2, which
was increased after cisplatin treatment (Fig 2E, Appendix Fig S2A,
see Appendix Fig S2B and C for PAX8 positivity and mutant TP53
pattern of nutlin unresponsiveness). Coincidentally, oncogenic
EphA2-pS897 increased in all six patient cells, whereas EphA2 auto-
phosphorylation showed an opposite pattern with EphA2-pY588 in
the untreated cells declining progressively after treatment with
increasing concentrations of cisplatin (Fig 2E, Appendix Fig S2A).
Thus, the pS897/pY588 ratio was significantly increased in these
patient-derived cells (Fig 2E and F; 5 lM cisplatin 3.0  1.3, 10 lM
cisplatin 4.5  1.7, 20 lM cisplatin 6.1  1.3-fold increase,
P ≤ 0.02).
The current suggested platinum chemotherapy for OC patients is
carboplatin, a non-inferior but less toxic platinum-derivate that also
causes less unspecific apoptosis in vitro (du Bois et al, 2003; Good-
isman et al, 2006). To validate the specific effect of platinum on
EphA2, OVCAR4 and OVCAR8 were treated with up to 80 lM carbo-
platin (higher concentrations than cisplatin due to lower chemical
reactivity; Alberts & Dorr, 1998). After treatment, EphA2 (total and
pS897) was enhanced and the tumor-suppressive EphA2-pY588
decreased in OVCAR4 (Fig 2G). As a result, carboplatin significantly
increased the pS897/pY588 ratio (Fig 2G and H; 3.0  0.2-fold at
80 lM carboplatin, P = 0.014), whereas the platinum-resistant
OVCAR8 had high pS897/pY588 prior and after treatment (Fig 2G
and H; 2.1  0.1-fold higher in untreated OVCAR8 than
corresponding OVCAR4, P = 0.048). Altogether, these results reveal
a previously unappreciated induction of a robust oncogenic EphA2
phosphorylation switch by platinum chemotherapy in HGSC cells.
Platinum triggers an oncogenic EphA2-S897
phosphorylation in vivo
To define the effect of platinum in EphA2 signaling in vivo, OVCAR4
cells were lentivirally transduced to express Renilla luciferase and
injected intraperitoneally in severe combined immunodeficient
(SCID) female mice. All mice developed tumors in the abdominal
cavity (Figs 3A and EV2A). These tumors grew as widely dissemi-
nated foci in the omentum and other peritoneal organs, coincident
with the accumulation of ascites, thus mimicking HGSC dissemina-
tion in patients (Fig EV2A; Kenny et al, 2011). Carboplatin effec-
tively reduced the tumor burden and eliminated the ascites (Fig 3B
and C; P ≤ 0.01). In the solid omental and peritoneal tumors, carbo-
platin had negligible effects on proliferation (Ki67), whereas apopto-
sis (TUNEL and clCasp3) was increased (Figs 3H and I, and EV2B–
D; P ≤ 0.042). However, residual tumor foci remained, modeling the
resistant metastatic lesions with potential for aggressive disease
progression in patients (Fig 3D; Pfisterer & Ledermann, 2006;
Armbruster et al, 2018). By immunofluorescence, total EphA2 and
the oncogenic EphA2-pS897 were enhanced in the residual carbo-
platin-treated tumors as compared to untreated controls (Fig 3E–H;
EphA2 1.4  0.4, EphA2-pS897 1.6  0.1-fold increase; P ≤ 0.009).
In the carboplatin-treated tumors, EphA2-pS897 and clCasp3 local-
ized to different tumor cells and areas (Fig 3H). These results
suggest that the treatment-escaping HGSC cells activated oncogenic
EphA2 signaling in response to platinum chemotherapy also in vivo.
EphA2 phosphorylation switch is associated with
platinum resistance
To address the possible relationship between EphA2 signaling and
platinum resistance, we used the human HGSC model of TYK-nu
Table 1. Patient information.
Patient OriginA Stage Residual tumor size BRCA status Platinum–taxane regimen Response Follow-up
OCKI_p01 HGS-O IVB 0 mm Mut Yes CR NED
OCKI_p02 HGS-O IIIC 0 mm WT Yes CR PD
OCKI_p03 HGS-O IVB > 2 cm Mut Yes PR PD
OCKI_p04 HGS-FP IIB 0 mm WT Yes CR NED
OCKI_p06 HGS-FP IIIC 0 mm WT Yes CR PD
OCKI_p10 HGS-FP IIIC 0 mm WT Yes CR NED
OCKI_p11 HGS-O IVB > 2 cm WT Yes PR PD
OCKI_p13 HGS-FP IIIC 0 mm WT Yes CR NED
OCKI_p20 HGS-FP IIIC 0 mm Mut Yes CR NED
OCKI_p22 HGS-FP IIIC < 5 mm WT Yes CR NED
OCKI_p25 HGS-FP IIIB < 1 cm WT Yes PD PD
OCKI_p27 HGS-FP IIIC 0 mm NA NA NA NA
OCKI_p28 CCC IIIC > 2 cm NA Yes NA NA
HGSC originA: O, ovary; FP, fallopian tube. Abbreviations: CCC, clear cell carcinoma; WT, wild type; Mut, mutant; CR, complete response; PR, partial response; PD,
progressive disease; NED, no evidence of disease; NA, no available data.
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Figure 1. Cisplatin treatment leads to EphA2 upregulation in ex vivo HGSC cultures.
A Confocal micrographs show cytokeratin 7 (CK7, green) and vimentin (red) in patient-derived HGSC cells cultured in 3D collagen for 7 days. Scale bars: 50 lm.
B Confocal micrographs of EphA2 (red) in HGSC cells cultured in 3D collagen for 7 days and treated for 72 h with 10 lM cisplatin (5 lM for OCKI_p01). The intensity of
EphA2 is comparable only between mock and treatment conditions for each patient. Scale bars: 20 lm.
C Chart illustrates EphA2 fold change after treatment. Mock is set to one. N = 3.
Data information: In (C), data are presented as mean fold change (SD). **P < 0.01. Exact P-values are provided in Appendix Table S10, Student’s t-test.
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cells and their resistant subline TYK-nu.R, originally generated by
continuous exposure to cisplatin (Yoshiya et al, 1989; Domcke
et al, 2013). In line with our OVCAR and patient cell results, plat-
inum treatment of TYK-nu enhanced EphA2 (total and pS897) and
reduced the tumor-suppressive EphA2-pY588 (Fig 4A), thus
increasing pS897/pY588 ratio (Fig 4B; 5 lM cisplatin 8.6  0.3,
10 lM cisplatin 8.0  0.4-fold increase, P ≤ 0.009). Moreover,
TYK-nu.R had 2.8  0.2-fold higher pS897/pY588 than TYK-nu
prior treatment (Fig 4A–D; P = 0.004), in a similar manner as with
the platinum-resistant OVCAR8 relative to the more sensitive
OVCAR4. Cisplatin further increased EphA2 pS897/pY588 also in
TYK-nu.R (Fig 4A and B; 10 lM cisplatin 2.6  0.4-fold increase,
P ≤ 0.033).
Importantly, carboplatin triggered an analogous oncogenic
switch via coincidently increased EphA2-pS897 and decreased
EphA2-pY588 in TYK-nu, while in TYK-nu.R, pS897/pY588 was
high with and without carboplatin (Fig 4C). Therefore, the EphA2
signaling switch occurs as a HGSC cell response to platinum
chemotherapy and is associated with increased treatment resistance
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Figure 2. OC cell lines and patient-derived cells undergo an EphA2 phosphorylation switch upon platinum treatment.
A, B EphA2 (total and phosphorylated at S897 or Y588) in OVCAR3, OVCAR4, and OVCAR8 after treatment with 0–20 lM cisplatin for 72 h was assessed by
immunoblotting (A) and quantified for pS897/pY588 ratio (B). N = 4.
C EphA2 (total and phosphorylated) in corresponding untreated cells. The same b-actin detection for these samples is shown in Appendix Fig S1B.
D Cytotoxicity assay results after cell treatment with 0–20 lM cisplatin for 72 h. N = 6.
E Quantitative assessment of EphA2 (total and phosphorylated) and pS897/pY588 ratio in early passage patient-derived HGSC cultures treated with 0–20 lM
cisplatin for 72 h (see immunoblots in Appendix Fig S2A). N = 6 patients, pooled.
F Corresponding EphA2 pS897/pY588 ratios for individual patient cells.
G, H EphA2 (total and phosphorylated) in OVCAR4 and OVCAR8 after treatment with 0–80 lM carboplatin for 72 h (G) along with pS897/pY588 quantification (H).
N = 3.
Data information: In (B, D–E, and H), data are presented as mean (SD). *P < 0.05, **P < 0.01, ***P < 0.001. Exact P-values are provided in Appendix Table S10, Student’s
t-test.
Source data are available online for this figure.
ª 2020 The Authors EMBO Molecular Medicine 12: e11177 | 2020 5 of 22



























































































































































Figure 3. Platinum treatment promotes ligand-independent oncogenic EphA2 phosphorylation in vivo.
A Bioluminescence images visualize mock- and carboplatin-treated OVCAR4 xenograft tumors (day 53; after 13-d i.p. treatment). Color scale unit: p/sec/cm2/sr.
B, C Charts illustrate the tumor growth (B) and ascites volumes at the end of the follow-up (C). Carboplatin treatment started on day 35. Bioluminescent unit: p/sec/
cm2/sr. N = 5 mice/group.
D, E Representative micrographs of hematoxylin–eosin staining (D) and EphA2-pS897 immunofluorescence (E) in the xenografts tumors. Scale bars: 100 lm (D), 10 lm
(E).
F, G Quantitative assessment of tumor EphA2 (F) and EphA2-pS897 (G). N = 5 mice/group.
H, I Confocal micrographs of tumor EphA2-pS897 (red) and cleaved caspase-3 (H; clCasp3, green) and corresponding clCasp3 quantification (I). Scale bars: 20 lm. N = 5
mice/group.
Data information: In (B and C; F and G; and I), data are presented as mean (SD). *P < 0.05, **P < 0.01. Exact P-values are provided in Appendix Table S10, Mann–
Whitney U-test.
Source data are available online for this figure.
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RSK activity mediates oncogenic EphA2-S897 phosphorylation in
OC cells
To uncover the mechanism of the EphA2-S897 phosphorylation, we
used inhibitors against the kinases reported to phosphorylate the
receptor in other cancers (Miao et al, 2009; Zhou et al, 2015;
Barquilla et al, 2016). As above, cisplatin increased EphA2-pS897 in
TYK-nu (Fig 4E). Inhibitors of MEK, upstream of ERK1/2-RSK
(UO126), and to less extent PKA (H89.2HCl) reduced the
constitutive and platinum-induced EphA2-pS897, whereas PI3K
inhibition, upstream of Akt (LY294002 and aPI3K BYL-719), had
minor effects on this phosphorylation (Fig 4E). Most effectively, the
RSK inhibitor (RSKi) BI-D1870 blocked EphA2-pS897 in TYK-nu
(Fig 4E and F; 58.8  21.2% reduction in the absence of cisplatin,
P = 0.003) and TYK-nu.R (Fig 4G).
Moreover, carboplatin triggered the activation of ERK1/2 and
RSK, indicated by increased ERK1/2-T202/Y204 and RSK-T359/S363



























































































0 2010 0 10 20














0 5 15 0 5 15


















0 15 30 0 15 30




































Figure 4. Oncogenic EphA2 signaling switch is associated with platinum resistance and mediated by treatment-activated ERK1/2-RSK axis in OC cells.
A, B Immunoblot images show EphA2 (A; total, pS897, and pY588) and corresponding pS897/pY588 ratios (B) of TYK-nu and TYK-nu.R after treatment with 0–10 lM
cisplatin for 72 h. N = 5.
C, D EphA2 (total and phosphorylated) in the cells treated (C) and untreated (D) with 0–80 lM carboplatin for 72 h.
E, F EphA2 (total and pS897) in TYK-nu after treatment with inhibitors against MEK (UO126, 10 lM), PKA (H89.2HCl, 10 lM), PI3K (LY294002, 10 lM) or its alpha
subunit (BYL-719, 5 lM), and RSK (BI-D1870, 10 lM) in combination with 0–10 lM cisplatin for 72 h (E). Corresponding EphA2-pS897 quantification for BI-D1870
treatment (F). N = 5.
G EphA2 (total and pS897) in TYK-nu.R treated with 0–20 lM cisplatin without or with 10 lM BI-D1870 for 72 h.
H, I EphA2, RSK, and ERK1/2 (total and phosphorylated) in TYK-nu (H) and OVCAR4 (I) treated with 0–30 lM carboplatin without or with 50 lM LJH685 for 72 h.
Data information: In (B and F), data are presented as mean (SD). *P < 0.05, **P < 0.01. Exact P-values are provided in Appendix Table S10, Student’s t-test.
Source data are available online for this figure.
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LJH685, with limited off-target effects (Aronchik et al, 2014),
prevented both the platinum-induced RSK activation and EphA2-
pS897 (Fig 4H and I; see Appendix Fig S3A for BI-D1870 and
LJH685 comparison). In contrast, upstream ERK1/2-pT202/Y204
was even increased by RSKi (Fig 4H and I). These results identify
ERK1/2-RSK axis as the platinum-activated pathway essential for
EphA2-S897 phosphorylation in OC cells.
Inhibition of RSK and EphA2-pS897 enhances EphA2-pY588,
concurrently reducing OC cell viability
To test whether the RSK-EphA2 axis inhibition affects platinum
resistance, OC cells were treated with cisplatin with and without
RSKi. While BI-D1870 alone had minor effects on OVCAR4 and
OVCAR8 viability, this treatment significantly sensitized the cells to
platinum (Fig 5A; reduction in viability: OVCAR4 52.9  8.2% at
5 lM cisplatin, OVCAR8 78.9  12.7% at 20 lM cisplatin,
P < 0.001). Consistently, OVCAR8 was sensitized to cisplatin by
LJH685 (Fig 5B, Appendix Fig S3B; 52.3  9.8% reduced viability
at 20 lM cisplatin, P = 0.011). Platinum-sensitive TYK-nu was less
affected by RSKi (Fig 5A and B), whereas the viability of TYK-nu.R
was markedly decreased relative to untreated control (Fig 5A;
64.0  11.1%, P = 0.002). Further, the combination of platinum
with RSKi effectively eliminated TYK-nu.R cells (Fig 5A; reduction
in viability: 62.8  33.3% at 10 lM cisplatin, P = 0.004).
Despite this close correlation between RSK-EphA2 axis and plat-
inum resistance, and contrary to results with other cell lines (Lan-
den et al, 2005a; Shen et al, 2013), siRNA-mediated EphA2
knockdown did not significantly alter TYK-nu and TYK-nu.R viabil-
ity or cisplatin sensitivity in 2D or 3D (Appendix Fig S3C and D).
EphA2 depletion increased, however, the poorly characterized
EphA2 interacting orphan receptor GPRC5A (Appendix Fig S3C). To
understand these results, we further assessed the effects of RSKi in
EphA2 in the cells with differential treatment responses. Notably,
LJH685 alone and combined with cisplatin increased tumor-suppres-
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Figure 5. RSK-EphA2-pS897 inhibition enhances EphA2-pY588 and sensitizes OC cells to platinum chemotherapy.
A, B Charts show OC cell viability after 72-h treatment with 0–20 lM cisplatin and 10 lM BI-D1870 (A; N = 4) or with 50 lM LJH685 (B; N = 3) as indicated.
C RSK and EphA2 (total and phosphorylated) in OC cells treated with 10 µM cisplatin and 25 µM LJH685 as indicated for 72 h.
D Charts illustrate the corresponding quantified inhibition of EphA2-pS897 and increase in EphA2-pY588 shown in (C).
Data information: In (A, B), data are presented as mean (SD). *P < 0.05, **P < 0.01, ***P < 0.001. Exact P-values are provided in Appendix Table S10, Student’s t-test.
Source data are available online for this figure.
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effectively sensitized to platinum (Fig 5C and D). Consistently, this
tumor-suppressive EphA2 axis was most prevalent in the untreated
cisplatin-sensitive TYK-nu, while the acute TYK-nu.R sensitivity to
LJH685 was coupled with increased EphA2-pY588 (Fig 5C and D;
NA after collapsed cell viability by combinatorial treatment).
Considering the EphA2-pS897 inhibition results (see Fig 4E), we
also tested the effect of Trametinib, an FDA approved MEKi (Wright
& McCormack, 2013; Odogwu et al, 2018), in cell responses to plat-
inum. Coincident with ERK1/2-pT202/Y204 inhibition, Trametinib
decreased viable OVCAR4 by over 40% compared to untreated
control, whereas the relative cell cisplatin sensitivity remained unal-
tered (Appendix Fig S3E and F). In vivo, Trametinib did not affect
carboplatin-induced apoptosis or decrease proliferation significantly
in our xenograft pilot experiment (Appendix Fig S3G–J). Therefore,
rather than broad MEK-ERK1/2 pathway inhibition or EphA2 knock-
down, the specific RSK-EphA2-pS897 blockade and consequent
reversal to tumor-suppressive EphA2-pY588 correlated with the
effective OC cell elimination and sensitization to platinum.
RSK regulates EphA2-associated orphan receptor GPRC5A,
controlling platinum resistance
To clarify the molecular mechanisms governing the EphA2 signaling
duality and treatment resistance, we analyzed the poorly character-
ized EphA2 interactor GPRC5A (Bulanova et al, 2017). In OC cells,
GPRC5A was detected as 41–46 kDa protein (Fig 6A). Unexpectedly,
the 41 kDa form diminished and the 46 kDa form became promi-
nent after treatment with cisplatin or LJH685 in both platinum-resis-
tant, RSKi-sensitive OVCAR8 and TYK-nu.R (Fig 6A and B;
P ≤ 0.025, TYK-nu.R NA after combinatorial treatment due to
collapsed cell viability). By immunofluorescence, cisplatin treatment
led to partial translocation of the otherwise intracellularly accumu-
lated GPRC5A to cell surface, thus enhancing co-localization with
EphA2 (S897-phosphorylated; see Fig 5C and D) in TYK-nu.R
(Fig 6C, Appendix Fig S4). Instead, RSK-EphA2-pS897 inhibition by
BI-D1870 led to EphA2-pY588 induction (see Fig 5C and D) coupled
with EphA2 downregulation with and without cisplatin, thus
impairing the cisplatin-induced receptor co-localization (Fig 6C,
Appendix Fig S4).
In TYK-nu, platinum-mediated increase in cell surface EphA2-
pS897 instead correlated with intracellular GPRC5A localization
(Fig 6C, Appendix Fig S4; see Fig 5C and D for EphA2-pS897
increase). Moreover, siRNA-mediated EphA2 depletion resulted in
stronger GPRC5A upregulation in TYK-nu than in TYK-nu.R
(Appendix Fig S3C). Taken together with EphA2 upregulation (total
and pS897) after GPRC5A partial knockdown upon platinum
treatment in TYK-nu, but not in TYK-nu.R (Appendix Fig S5A–C),
these results suggest that EphA2 and GPRC5A are mutually nega-
tively regulated in the platinum-sensitive cells. In cisplatin-resistant
TYK-nu.R, the platinum-induced GPRC5A-EphA2-pS897 co-regula-
tion was in turn impaired by RSKi through EphA2-pY588 activation
coupled to EphA2 downregulation, coincident with the effective
treatment response.
Consistent with the RSKi results, knockdown of RSK1 and/or
RSK2, which are the cancer-associated RSKs highly expressed in OC
cells (Fig EV3A), inhibited the platinum-induced EphA2-pS897
(Fig 6D and E). Coincidentally, the viability of cisplatin-treated
TYK-nu.R was reduced (Fig 6F; control siNT 24.9  11.2% vs.
siRSK1 9.2  4.2%, siRSK2 8.3  6.6%, siRSK1/2 8.0  8.0%,
P ≤ 0.016). In OVCAR4 and OVCAR8, the EphA2 oncogenic switch
was less affected by RSK1 knockdown, but effectively reversed to
EphA2-pY588 after RSK2 knockdown (Fig EV3B). Notably, RSK1
depletion effectively suppressed GPRC5A (46 kDa) upon platinum
treatment in the resistant OVCAR8 and TYK-nu.R, coincidentally
enhancing apoptosis, indicated by increased cleaved PARP in TYK-
nu.R (Figs 6E and EV3B). In the absence of cisplatin, RSK2 deple-
tion increased cleaved PARP, whereas the proliferation marker
PCNA was generally less affected by RSK1/2 knockdown (Fig 6E).
Moreover, RSK1 or GPRC5A overexpression increased OVCAR4
and OVCAR8 viability after cisplatin treatment (Fig EV3C–E). Over-
expression of EphA2 and RSK2 to some extent also enhanced
OVCAR4 resistance to cisplatin (Fig EV3C and F; P ≤ 0.048 at 5 lM
cisplatin). Therefore, cisplatin activated the EphA2 tyrosine–serine
phosphorylation switch through RSK(1/)2 coincident with RSK1
(/2)-dependent GPRC5A co-regulation to promote OC cell evasion
from platinum-induced apoptosis.
Combinatorial RSKi-platinum treatment induces apoptosis in 3D
co-culture and in vivo
EphA2 signaling alters cell interactions with the TME (Gucciardo
et al, 2014; Zhou & Sakurai, 2017). Therefore, to assess the regula-
tion of apoptosis in the context of relevant cell and ECM interac-
tions, we generated mono- and co-culture spheroids of OVCAR8-
RFP and patient-derived cancer-associated fibroblasts (OCKI_p22
CAF) and cultured them in 3D collagen. In OVCAR8-RFP monocul-
tures, cisplatin treatment for 20 h enhanced apoptosis (clCasp3),
whereas clCasp3 remained less affected by LJH685 alone (Fig 7A
and B, and Appendix Fig S6A). Of note, apoptosis was further
increased after combining LJH685 with cisplatin (Fig 7A and B). In
CAF monocultures, apoptosis remained unaltered by the treatments
(Fig 7A and B). Notably, in 3D co-culture with CAFs, cisplatin as
▸Figure 6. GPRC5A regulation defines OC cell responses to RSK1/2-EphA2-pS897 inhibition.A, B Immunoblot images (A) and quantification (B) show GPRC5A 46/41 kDa ratios in OC cells treated with 0–10 µM cisplatin and with 25 µM LJH685 alone or as a
combination for 72 h. The ratio in mock cells was set to 1. N = 4.
C Confocal micrographs of EphA2 (red) and GPRC5A (green) in TYK-nu and TYK-nu.R treated with 5 µM cisplatin and 10 lM LJH685 as indicated for 72 h. Arrows
point co-localization of the receptors. Scale bars: 20 lm.
D, E EphA2 (total and phosphorylated), RSK1/2, and GPRC5A in TYK-nu (D) and these proteins coupled with PARP and PCNA in TYK-nu.R (E) were assessed by
immunoblotting after RSK1/2 knockdown for 2 days and following treatment with 0–5 lM cisplatin for 72 h. Asterisks indicate unspecific bands.
F Chart illustrates the viability of the RSK1/2-depleted TYK-nu.R after cisplatin treatment. N = 3.
Data information: In (B and F), data are presented as mean (SD). *P < 0.05, **P < 0.01. Exact P-values are provided in Appendix Table S10, Student’s t-test.
Source data are available online for this figure.
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well as LJH685 alone failed to induce OVCAR8-RFP apoptosis,
whereas the combinatorial LJH685-cisplatin treatment effectively
increased clCasp3 (Fig 7A and B; P = 0.022).
Importantly, combination of LJH685 with cisplatin further
enhanced platinum-induced apoptosis in the spheroid co-cultures of
patient-derived OCKI_p13 HGSC cells and OCKI_p22 CAFs in 3D
collagen (Fig 7C and D; see Appendix Fig S6B for morphological
characterization of the patient HGSC 3D mono- and co-cultures).
In vivo, combinatorial RSKi-platinum treatment of the OVCAR4
xenografts for 48 h likewise increased apoptosis significantly
(Fig 7E and F; tumor TUNEL increased 2.5  1.8-fold, P = 0.014),
whereas proliferation (Ki67) remained unaltered (Fig 7G and H).
Patient-derived GPRC5Ahigh HGSC cells are sensitive to
combinatorial RSKi-platinum treatment
To validate the clinical relevance of our findings, we next
assessed RSK, EphA2, and GPRC5A by immunofluorescence in
human HGSC tumor tissue sections. Notably, all these proteins
showed higher expression in HGSC than in the stroma (Fig 8A,
Appendix Fig S7A). By immunoblotting of patient-derived cells,
EphA2 (total and phosphorylated), GPRC5A, and RSK showed
variable expression in the cancer cells, whereas GPRC5A was
undetectable and RSK low in patient-derived CAFs (Fig 8B). As
expected, CAFs expressed PDGFRb and FSP1, and cancer cells E-
cadherin and PAX8, whereas both cell types were positive for
vimentin and N-cadherin (Fig 8B).
To assess the specificity of the RSKi-platinum response, HGSC
patient-derived cancer and stromal cells as well as normal fibrob-
lasts were treated with RSKi alone and combined with cisplatin.
Notably, cisplatin increased EphA2 and pS897/pY588, and BI-D1870
blocked both the constitutive and cisplatin-induced EphA2-pS897 in
the HGSC cells with high GPRC5A, concurrently increasing tumor-
suppressive EphA2-pY588 (Fig 8C and D, Appendix Fig S7B). Treat-
ment with LJH685 likewise reverted the platinum-induced EphA2
switch (Appendix Fig S7C). Coincident with this signaling reversal,
RSKi significantly sensitized the cells to platinum (Fig 8E; reduction
in viability at 20 lM cisplatin: OCKI_p02 68.1  40.1%; OCKI_p06
48.7  21.4%, P ≤ 0.027). In contrast, RSKi neither reverted effi-
ciently the platinum-induced EphA2 switch in cells with low
GPRC5A (Appendix Fig S7D and F) nor altered the viability of
patient-derived CAFs, mesothelial cells, or CCL-137 embryonic lung
fibroblasts (Fig 8F and G, Appendix Fig S7I). While cisplatin treat-
ment variably induced and RSKi reduced EphA2-pS897, EphA2-
pY588 was not restored upon cisplatin treatment in the benign cells
(Fig 8H, Appendix Fig S7G, H and J).
Notably, GPRC5A localization in ex vivo 3D cultures of the RSKi-
sensitive HGSC cells resembled the corresponding pattern in TYK-
nu.R, including the platinum-induced translocation to cell surface,
leading to co-localization with EphA2 (Fig 8I; see Fig 6C for TYK-
nu.R). The EphA2-GPRC5A co-localization was likewise increased
in the RSKi-sensitive xenograft tumors after carboplatin treatment
in vivo (Fig EV4A and B; 7.2  0.7-fold increase, P = 0.0002). Alto-
gether, these results reinforce the link between cancer cell-expressed
◀ Figure 7. RSKi combinatorial treatment induces apoptosis in 3D co-culture and in vivo.A Confocal micrographs show cleaved caspase-3 (clCasp3, green), mRFP (orange), and phalloidin (F-actin, red; only shown for CAF) in 3D OVCAR8-RFP and OCKI_p22
CAF mono- and co-cultures treated without or with 20 µM cisplatin or 25 µM LJH685 alone or in combination for 20 h. Scale bars: 100 lm.
B Quantitative assessment of clCasp3+ cells in the 3D cultures. N = 4.
C Confocal micrographs show cytokeratin 7 (CK7, green) and phalloidin (F-actin, red) in 3D patient OCKI_p13 mono- and co-culture with OCKI_p22 CAF treated
without or with 20 µM cisplatin or 25 µM LJH685 alone or in combination for 20 h. Scale bars: 50 lm.
D Quantitative assessment of clCasp3+ OCKI_p13 cells in 3D co-cultures of patient-derived cells. N = 4.
E–H Immunohistochemistry images and quantifications of TUNEL (E, F) and Ki67 (G, H) in OVCAR4 xenografts in mock (N = 4)-, carboplatin (N = 4)-, and
carboplatin + BI-D1870 (N = 5)-treated mice. Scale bars: 100 lm.
Data information: In (B and D, F, and H), data are presented as mean (SD). *P < 0.05, **P < 0.01. Exact P-values are provided in Appendix Table S10, Student’s t-test
(B, D) and Mann–Whitney U-test (F, H).
Figure 8. RSK-EphA2-pS897 inhibition specifically sensitizes GPRC5Ahigh HGSC cells to platinum chemotherapy.
A Representative confocal micrographs show EphA2 (red), RSK (green: top), and GPRC5A (green: bottom) in frozen sections of HGSC patient tumors. S indicates the
stroma. Scale bars: 50 lm.
B Indicated proteins and EphA2 phosphorylation were assessed by immunoblotting in patient-derived HGSC cells and CAFs.
C GPRC5A in earlier (top) and later passage (bottom) HGSC cells. See normalized GPRC5A relative to OCKI_p01 below the immunoblot images.
D Charts illustrate EphA2-pS897 inhibition (circles) and EphA2-pY588 increase (squares) by 10 µM BI-D1870 alone (unbroken line) or in combination with 0–10 µM
cisplatin (dotted line) in the GPRC5Ahigh HGSC cells. See Appendix Fig S7B for immunoblots.
E Cell viability of the GPRC5Ahigh OCKI_p02 and OCKI_p06 after treatment with a combination of 0–20 µM cisplatin and 10 µM BI-D1870 for 72 h. N = 3.
F, G Cell viability upon 72-h combinatorial treatment with 0–20 µM cisplatin and 25 µM LJH685 in patient-derived CAFs (F; N = 3) and 10 µM BI-D1870 in mesothelial
cells (G; N = 3).
H Chart illustrates the changes in EphA2-pS897 and EphA2-pY588 by BI-D1870 alone and with cisplatin in mesothelial cells. Upon combination with 10 µM cisplatin
for 72 h, 10 µM BI-D1870 decreased EphA2-pS897 and EphA2-pY588. See Appendix Fig S7J for immunoblot.
I Confocal micrographs of EphA2 (red) and GPRC5A (green) in primary OCKI_p06 patient cells cultured in 3D collagen for 4 days before 72-h treatment with or
without 10 µM cisplatin. Scale bars: 20 lm.
Data information: In (E–G), data are presented as mean (SD). *P < 0.05. Exact P-values are provided in Appendix Table S10, Student’s t-test.
Source data are available online for this figure.
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GPRC5A, the RSK1/2-EphA2 signaling inhibition, and treatment
sensitivity of HGSC cells.
High GPRC5A is associated with poor survival and chemotherapy
resistance in HGSC patients
Since GPRC5A remains uncharacterized in clinical HGSC, we
performed histological analysis of tissue microarrays (TMA)
containing samples from primary and metastatic tumors of 126
treatment-naı̈ve HGSC patients (Fig 9A, Appendix Table S1). The
maximum GPRC5A intensity in cancer cells was classified as low
(negative, mild, or moderate) or high (Fig 9B). There was no signifi-
cant correlation between GPRC5A intensity in primary vs. metastatic
cores, indicating that GPRC5A protein expression was independent
of the tumor site (Appendix Table S2). The GPRC5A grading did not
correlate with clinico-pathological variables except for FIGO stage in
primary tumors (Appendix Table S3; P = 0.047). Thus, the metric
maximum intensity of GPRC5A in cancer cells was not dependent
on most analyzed variables.
To examine the correlation between GPRC5A and patient
outcome, we performed survival analyses for primary and meta-
static tumors separately. In both groups, high GPRC5A was signifi-
cantly associated with worse overall survival (OS) and with shorter
progression-free survival (PFS) in the metastatic tumors (Fig 9C and
D, Appendix Table S4; OS: P = 0.044 and 0.012, PFS: P = 0.009). By
univariate analysis, all clinico-pathological variables (except for
FIGO stage and type of surgery) and GPRC5A were significantly
associated with worse OS in both primary and metastatic cases
(Appendix Table S5). Additionally, GPRC5A was associated with
shorter PFS in the metastatic tumors (Appendix Table S6). In line
with these survival results, Cox multivariate analysis validated the
association of GPRC5A with worse OS in both groups
(Appendix Table S5), whereas shorter PFS was significantly associ-
ated with GPRC5A only in metastatic cases (Appendix Table S6).
Of note, GPRC5A in primary tumors was inversely correlated
with the reduction in tumor burden at the end of treatments, defined
by the objective response rate (ORR), and with platinum sensitivity,
considering sole administration or combination with taxane (Fig 9E,
Appendix Table S7; P = 0.034 and 0.011). In The Cancer Genome
Atlas (TCGA) OC mRNA dataset, GPRC5A was associated with
worse OS survival (Fig EV5A; 40% highest vs. 40% lowest GPRC5A
expressing patients, P = 0.045) and co-expressed with EphA2, for
which we did not obtain reliable detection in the TMA (Fig EV5B;
http://cancergenome.nih.gov/). Using an independent publicly avail-
able cohort with mRNA data from 125 treatment-naı̈ve HGSC
patients (Pils et al, 2012), we further validated the potential of
combined GPRC5A and EphA2 expression to predict patient PFS
(Fig 9F–H; P = 0.020, NS for EphA2 or GPRC5A alone). The mRNA
for RSK1-4 did not improve the significance of this predictive power
(Figs 9I and EV5C–F). These results indicate that the GPRC5A-
EphA2 axis can predict poor platinum-based chemotherapy
responses and shorter survival in patients with HGSC.
Discussion
Surgery and platinum-based chemotherapy, the standard of care for
HGSC patients, often efficiently eliminate macro-metastases and
cancer cells accumulated in ascites. Yet micro-metastases remain,
allowing recurrence of increasingly resistant disease, which is a
major challenge for successful clinical care. Here, using established
chemo-sensitive and chemo-resistant HGSC cell models in vitro and
in vivo, as well as treatment-naı̈ve primary and early passage
ex vivo cultures from HGSC patients, we uncovered a robust mecha-
nism, whereby cancer cells gain platinum resistance via the treat-
ment-induced, adaptive RSK1/2-EphA2-GPRC5A signaling switch.
Clinical evidence indicates that even after initial drug response,
majority of relapsed HGSCs repeatedly respond to platinum-based
chemotherapy (Pfisterer & Ledermann, 2006). Therefore, improved
understanding of the signaling pathways governing the phenotypic
plasticity of the resistant micro-metastatic cells, rather than focus only
on the emergent genetically chemo-resistant clones, can provide new
strategies to develop more effective treatments. Indeed, signals for
cancer invasiveness and stemness as well as epithelial-to-mesench-
ymal transition have been suggested as mechanisms for increased
chemoresistance (Diepenbruck & Christofori, 2016), yet how such
pathways operate and evolve in the treatment-resisting cells upon
chemotherapy remains unclear. Our results identify one such mecha-
nism via ERK1/2-RSK1/2 kinase pathway activated in OC cells by
platinum chemotherapy. Besides DNA damage, platinum is known to
induce oxidative stress/ROS-related ERK1/2 activation in different
types of malignant and non-malignant cells (Dasari & Tchounwou,
2014). Based on our results, this will lead to EphA2-S897 phosphory-
lation, previously shown to mediate stemness, invasion, and metasta-
sis in different types of cancer (Zhou & Sakurai, 2017).
After encouraging pre-clinical data showing reduced tumor
growth and increased taxane response after EphA2 depletion (Lan-
den et al, 2005b; Shen et al, 2013; Petty et al, 2018), a clinical trial
is testing direct EphA2 inhibition in advanced metastatic cancers
(NCT01591356, https://clinicaltrials.gov). We found, however, that
the effective RSKi treatments were tightly coupled with the induc-
tion of tumor-suppressive EphA2-pY588. Therefore, our results
suggest that instead of ablation of both tumor-suppressive and onco-
genic receptor activities, the reversal of the EphA2 oncogenic signal-
ing switch may better correlate with effective HGSC sensitization to
platinum-based chemotherapy.
In our HGSC cell cultures and ex vivo models, pharmacological
RSK inhibition blocked the activation of the tumor-promoting EphA2
activity, which in turn led to enhanced canonical tumor-suppressive
EphA2-pY588 signaling, coincidentally sensitizing the cells to plat-
inum-induced apoptosis. These results help to explain the previous
findings that RSK2 gene silencing increases OC cell sensitivity to
cisplatin, and RSK inhibition with BI-D1870 reduces tumor growth
and improves survival in xenograft models (van Jaarsveld et al,
2013; Hammoud et al, 2016). Furthermore, our knockdown results
reveal specific contributions of RSK1 and RSK2 in the oncogenic
switch, including active RSK1 function in the platinum-induced
GPRC5A regulation coupled to apoptosis evasion of the platinum-
resistant cancer cells. This is noteworthy since CAFs lacking
GPRC5A remained unaffected by RSKi addition to cisplatin treat-
ment, whereas the combinatorial treatment specifically induced OC
cell apoptosis in 2D and 3D. While no RSKi has entered clinical trials,
possibly due to off-target effects and toxicity or suboptimal pharma-
cokinetic properties, the upstream MEKi Trametinib is in clinical use
for certain other cancers (Faghfuri et al, 2018). In our cell and xeno-
graft pilot experiments, Trametinib–carboplatin combination did
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Figure 9. High GPRC5A is associated with poor survival and chemotherapy resistance in HGSC patients.
A Flow diagram of patients for the HGSC TMA.
B Representative immunostainings for GPRC5A scoring in HGSC primary and metastatic tumors. For maximum intensity scores, an optical 4-point scale (0: negative,
1: mild, 2: moderate, and 3: high) was used. For survival analyses, a 2-point scale (low: scores 0–2 and high: score 3) was used. Scale bars: 200 lm.
C, D Kaplan–Meier survival curves illustrate the overall (OS) and progression-free (PFS) survival of patients with high or low GPRC5A. In primary tumors, mean OS for
GPRC5Ahigh was 39 months vs. 56 months for GPRC5Alow (C). In patients with metastatic tumors, mean OS for GPRC5Ahigh was 37 months vs. 60 months for
GPRC5Alow. Mean PFS in metastatic tumors was 20 months for GPRC5Ahigh vs. 35 months for GPRC5Alow (D). No significant difference in mean PFS in primary
tumors.
E Correlation of maximum GPRC5A intensity with objective response rate (ORR) and treatment sensitivity (platinum alone or in combination with taxane).
F–I Kaplan–Meier survival estimates for the PFS of patients with high or low (top 25% vs. bottom 25%) GPRC5A (F), EPHA2 (G), GPRC5A + EPHA2 (H), and
GPRC5A + EPHA2 + RSK1(RPS6KA1) + RSK2(RPS6KA3)-combined (I) mRNA expression. Mean PFS for GPRC5A + EPHA2high was 15 months vs. 26 months for
GPRC5A + EPHA2low (H). Mean PFS for GPRC5A + EPHA2 + RPS6KA1/3high was 14 months vs. 31 months for GPRC5A + EPHA2 + RPS6KA1/3low (I).
Data information: In (C, D and F–I), logrank test was used. In (E), Pearson chi-square test was used.
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not, however, induce more apoptosis than carboplatin alone,
suggesting different modes of MEKi action from the specific EphA2-
GPRC5A signaling reversal by RSKi-platinum combination. Since
MEKi can trigger broad effects in, e.g., cell cycle regulation, possibly
hindering the RSK-dependent cancer cell sensitization to platinum
cytotoxicity, our results warrant further RSKi investigation and
development for a platinum combination.
Another challenge for improved HGSC treatments is the lack of
biomarkers for disease aggressiveness and specific treatment
responses. Currently, BRCA1/2 mutations, which deprive the cells
from efficient homologous recombination (HR) DNA repair, to some
extent predict platinum chemotherapy response and are used to
stratify patients for promising combinatorial PARP inhibitor treat-
ments (Ledermann et al, 2016; Coleman et al, 2017). Moreover,
functional HR deficiency assays have been able to score HR defi-
ciency ex vivo, predicting not only platinum response but also
patient survival (Tumiati et al, 2018). We found that the platinum-
induced oncogenic RSK1/2-EphA2 signaling switch was coupled to
EphA2-GPRC5A co-localization. As yet poorly understood, the
context-dependent functions of GPRC5A include facilitating HR
DNA repair, cell proliferation, and migration, as well as cell survival
under hypoxia (Sokolenko et al, 2014; Greenhough et al, 2018; Liu
et al, 2018). Such functions could be regulated by GPRC5A phos-
phorylation, since crosstalk of this receptor with EGFR induces
GPRC5A phosphorylation and switch from tumor-suppressive to
oncogenic activities in lung cancer (Lin et al, 2014; Wang et al,
2016). In our experiments, RSK1 depletion impaired the platinum-
dependent GPRC5A regulation coincident with increased apoptosis
(cleaved PARP). Since GPRC5A can be transcriptionally suppressed
by TP53, which is mutated in essentially all HGSCs, GPRC5A induc-
tion can occur frequently in OC (Wu et al, 2005; Domcke et al,
2013). Our results from histological analysis of GPRC5A in primary
and metastatic tumor specimens of advanced HGSC cohort, coupled
to data from publicly available mRNA expression datasets, revealed
the potential of this receptor as a biomarker for HGSC abysmal
outcome and poor chemotherapy response, and also for aiding at
the stratification of the unresponsive patients for treatment sensiti-
zation through novel combinatorial therapies, such as the RSK1/2-
EphA2-pS897 pathway inhibition.
To conclude, we have discovered a robust platinum-induced
oncogenic signaling switch along RSK1/2-EphA2-GPRC5A axis
which contributes to chemotherapy-driven adaptive resistance in
HGSC. Our results raise the question whether combinatorial targeted
approaches such as RSK inhibition would enable overcoming OC
adaptive platinum resistance. Additionally, our findings on GPRC5A
predicting poor survival and treatment response could potentially
fill in for the gap of clinically applicable biomarkers that are greatly
needed to improve OC treatment scheme.
Materials and Methods
Study approval
The Swedish Ethical Review Agency (Etikprövningsmyndigheten)
approved the collection of samples from patients with metastatic
HGSC (2016/1197-31/1, 2016/2060-32) and the collection of tumor
tissue for the TMA study (2012/539-31/1). In both cases, written
informed consent was received from participants prior to inclusion
in the studies. All experiments were performed according to the
principles set out in the World Medical Association Declaration of
Helsinki and the Department of Health and Human Services
Belmont Report. OC tumor xenograft experiments were approved by
the National Animal Experiment Board in Finland (ESAVI/8983/
04.10.07/2015) and the Animal Experiment Board in Osaka City
University in Japan (19001) and performed in compliance with ethi-
cal regulations for animal experiments and welfare.
Patient samples
Abdominal ascites fluid and omental tumors were collected at the
Karolinska University Hospital (see Table 1). Isolation of HGSC cells
from ascites fluid was performed immediately after acquisition.
After centrifugation at 3,200 g for 10 min at 4°C, the supernatant
was filtered using a 0.22-lm strainer to obtain cleared fluid used as
supplement for cell culture media. If needed, red blood cells were
lysed from the cell pellet by using Tris-buffered ammonium chloride
solution (Tris-NH4Cl). Multicellular clusters were collected from the
cell suspension using 45-lm strainer and re-suspended in 1:1
DMEM:F12 medium with 100 mg/ml penicillin/streptomycin and
10% clarified ascites. Cells were cultured at 37°C in 5% CO2 incuba-
tor and routinely checked using MycoAlertPlusTM Mycoplasma
Detection Kit (Lonza). All experiments were performed in complete
media (i.e., containing clarified ascites). For CAF isolation, fresh
omental tumors were dissected into small explants and cultured on
collagen type I (50 lg/ml, Sigma)-coated dishes in fibroblast
medium (Fibroblast Medium Kit, Innoprot). The patient-derived
cells were characterized by immunofluorescence of epithelial and
stromal markers immediately after isolation and during culture.
The characterization of cell cultures was corroborated by p53
immunofluorescence of mock- and nutlin-treated cells (16-h treat-
ment with 10 lM nutlin), considering that nutlin selectively stabi-
lizes wild-type TP53 and that majority of HGSC have TP53
mutations (Domcke et al, 2013). Patient-derived CAFs and ARN8
wild-type TP53 cells as well as mutant TP53 OVCAR8, TYK-nu, and
TYK-nu.R were used as controls. HGSC cells that responded to
nutlin treatment (wild-type TP53) were classified as mesothelial
cells and cultured as above.
Cell lines
NIH:OVCAR3, OVCAR4, and OVCAR8 (National Cancer Institute,
USA) were maintained in RPMI and TYK-nu and TYK-nu.R (Japa-
nese Collection of Research Bioresources Cell Bank; Japan) in MEM
(all classified as highly likely or likely human HGSC cell lines;
Domcke et al, 2013). ARN8 melanoma cells and CCL-137 fibroblasts
(American Type Culture Collection; USA) were maintained in
DMEM. All culture media were supplemented with 10% FBS,
100 mg/ml penicillin/streptomycin, and 10 lg/ml insulin (NIH:
OVCAR3 only). The cells were cultured and checked for mycoplasma
as above.
Cell spheroids and 3D collagen matrices
For the mono- and co-culture spheroids, OVCAR8 cells were trans-
fected to express recombinant histone H2A-red fluorescent protein
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(OVCAR8-RFP). Pure pool of RFP-positive colonies was collected by
fluorescent-activated cell sorting and seeded with patient-derived
CAFs (1:5 ratio, 3 × 105 cells/ml) on ultra-low attachment 96-well
plates (Corning) and incubated for 48 h at 37°C before embedding
in 3D collagen. Mono- and co-culture spheroids of patient-derived
HGSC cells with patient-derived CAFs were generated as above.
Rat tail collagen type I was dissolved in 0.3% acetic acid to
4.5 mg/ml stock and diluted to final concentration of 2.25 mg/ml in
2× MEM. pH was adjusted to 7.5–8 with sodium hydroxide. Cells
(1.75 × 106 cells/ml) and preformed spheroids were embedded in
40 ll collagen (in 10 ll for cytotoxicity assays) and incubated at
37°C up to 7 days before subjecting cells to cytotoxicity assays or
immunofluorescence.
siRNA knockdown and cDNA overexpression
siRNA against human EphA2 (GE Healthcare, Dharmacon: L-
003116-00-0005), GPRC5A (QIAGEN: GPRC5A#2 SI00058604 and
GPRC5A#5 SI02225734; Appendix Table S9), RSK1 (RPS6KA1; Dhar-
macon: L-003025-00-0005), RSK2 (RPS6KA3; Dharmacon: L-003026-
00-0005), and non-targeting control siRNA (QIAGEN: SI03650318)
were transfected in cells using Lipofectamine 2000 (Thermo
Scientific).
Cells were transfected with pcDNA3.1-His-V5 vector encoding
human EphA2 (Sugiyama et al, 2013), pKH3-human RPS6KA1/
RSK1 plasmid (gift from J. Blenis; Addgene plasmid #13841; http://
n2t.net/addgene:13841; RRID: Addgene_13841; Richards et al,
2001), pCMV3 N-HA-tagged human RPS6KA3/RSK2 plasmid (Sino
Biological), and corresponding empty vectors for mock controls by
using FuGENE HD (Promega). For GPRC5A stable overexpression,
293-FT cells were transfected with pLenti-C-Myc-DDK vector
containing GPRC5A cDNA, VSV-G envelope plasmid, and pCMV-
d8.91 packaging plasmid using Lipofectamine 2000. The medium
was changed 6 h after transfection, and the viral supernatants were
collected after 4 days, passed through a 0.45-lm filter and used for
transduction; controls were generated with the empty vector.
Drug treatment, inhibitor treatment, and cytotoxicity assay
Inhibitors were purchased from SelleckChem (H89.2HCl, BI-D1870,
LJH685, Trametinib) or Cell Signaling Technologies (UO126,
LY294002, BYL-719) and diluted in DMSO. Refametinib (Chemietek)
was diluted in water.
For combinatorial treatments, cells were treated with the indi-
cated inhibitors for 30 min before addition of cisplatin (Sigma) or
carboplatin (SelleckChem). Cytotoxicity was assessed after 72 h
using CellTiter-Glo Luminescent Cell Viability Assay (Promega) for
5–20 min before luminescence detection.
Antibodies
The antibodies used were as follows: primary antibodies against
cleaved caspase-3 (Asp175 Alexa Fluor 488 Conjugate, immunoflu-
orescence (IF) 1:50), E-cadherin (24E10, #3195S, immunoblotting
(WB) 1:1,000), EphA2_pS897 (#6347, WB 1:750, IF 1:100),
EphA2_pY588 (#12677, WB 1:750), ERK1/2 (#9107S, WB 1:500),
ERK1/2_pT202/Y204 (#9101, WB 1:500), PARP (46D11, #9532, WB
1:1,000), PCNA (D3H8P, #13110, WB 1:1,000), RSK1 (D6D5, #8408,
WB 1:1,500), RSK2 (D21B2 XP, #5528, WB 1:1,500), RSK1/2/3
(#9355, WB 1:750, IF 1:25), and RSK_pT359/S363 (#8753, WB
1:750) all from Cell Signaling Technologies. Primary antibodies
were purchased from Santa Cruz Biotechnology against EphA2 (C-3,
# sc-398832, WB 1:750), p53 (DO-1, # sc-126, IF 1:200), PDGFRb
(D6, # sc-374573, WB 1:500), vimentin (V-9, # sc-6260, WB 1:2000,
IF 1:100), b-actin (C-4, # sc-47778, WB 1:2,000), and b-tubulin (D-
10, # sc-5274, WB 1:500). Primary antibodies against CK7 (OV-TL
12/30, Invitrogen, MA5-11986, WB 1:1,000, IF 1:100), EphA2 (ECD,
R&D Systems, #AF3035, IF 1:100), FSP1 (AT1C3, LifeSpan Bios-
ciences, LS-C755562, WB 1:750), GAPDH (Sigma, Atlas Antibodies,
# G8795, WB 1:15,000), GPRC5A (Sigma, Atlas Antibodies
HPA007928, WB 1:1,000, IF and immunohistochemistry (IHC)
1:250), Ki67 (Leica, Biosystems, #ACK02, IHC 1:200), N-cadherin
(BD Transduction Laboratories, # 610920, WB 1:1,000), and PAX8
(Proteintech, #10336-1-AP, WB 1:2500, IF 1:100) were used.
Immunoblotting
Cells were lysed on ice with RIPA lysis buffer (50 mM Tris–HCl pH
7.4, 150 mM NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate)
supplemented with 5 mM EDTA, protease inhibitor (cOmplete
ULTRA tablet, Sigma), and phosphatase inhibitor (PhosSTOP tablet,
Sigma). The lysates were cleared by centrifugation at 21,130 g for
15min at 4°C, and protein concentrations were determined using
the Pierce BCA Assay (Thermo Scientific). Lysates were mixed with
5× sample buffer (0.3 M Tris–HCl pH 6.8, 50% glycerol, 10%
sodium dodecyl sulfate, 0.05% bromophenol blue) containing
0.5 M dithiothreitol and heat-denatured at 95°C for 10 min before
separation in 4–20% Mini-PROTEAN TGX Precast Protein Gels (Bio-
Rad) and transferred to Trans-Blot Turbo Mini Nitrocellulose Trans-
fer Packs (Bio-Rad). Membranes were blocked for 45 min with 5%
milk (Cell Signaling Technologies) or 3% fish gelatin (Sigma) in
Tris-buffered saline (TBS; 10mM Tris, pH 7.6, 150mM NaCl) and
probed with primary antibody in TBS 0.1% Tween-20 (TBS-T) with
5% milk or 3% fish gelatin at the recommended dilutions at 4°C
overnight. Membranes were incubated with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Dako) or with IRDye
Subclass-Specific Antibodies (LI-COR Biosciences) diluted in TBS-T
for 1 h at RT, and the signal was detected using ECL chemilumines-
cent detection reagent (GE Healthcare) and visualized using
ChemiDoc Imaging System (Bio-Rad) or using Odyssey Imaging
System (LI-COR Biosciences).
Metastatic in vivo ovarian cancer model
293-GPG cells were transfected with the pMx-Renilla luciferase–GFP
fusion reporter plasmid using Lipofectamine 2000. Viral super-
natants were obtained and processed as described above and used
for OVCAR4 transduction. To mimic the spread of OC cells as clus-
ters in ascites, 0.5 × 106 cells as preformed spheres in a mixture with
2.5 × 106 cells as single cell suspension in sterile saline were injected
intraperitoneally (i.p.) into 6-week-old female ICR-SCID C.B-17
(IcrHanHsd-Prkdcscid, Envigo) mice (N = 10). Tumor growth was
followed by noninvasive bioluminescence imaging after i.p. injection
of coelenterazine (35 lg in 100 ll PBS; Synchem) using Xenogen
IVIS 100 imaging system (PerkinElmer). Carboplatin treatment
(every 4 days, total of four doses; Accord) started on week 5
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(25 mg/kg i.p. in sterile saline, N = 5). Control group (N = 5)
received sterile saline injections. All mice received seven i.p. injec-
tions of an inert vehicle (30% PEG400 + 0.5% Tween80 + 5%
Propylene glycol) used for an additional RSKi-treated group for
which data are excluded from Results and Fig 3A due to extensive
inhibitor liver toxicity. Mice were sacrificed on week 7.
In a separate experiment, the above model (CB17/IcrJcl-Prkdcscid,
CLEA) was used to evaluate MEKi. Carboplatin treatment (every
4 days, total of three doses; SelleckChem) started on day 25
(15 mg/kg i.p. in sterile saline, N = 4). Trametinib was additionally
administered daily (1 mg/kg by oral administration in 4%
DMSO + Corn oil, N = 5). Control group (N = 4) received injections
of sterile saline and was also subjected to oral administration of 4%
DMSO + Corn oil (this vehicle was also administered to carboplatin-
treated mice). Mice were sacrificed on day 35.
A third independent proof-of-principle experiment was
conducted (CB17/IcrJcl-Prkdcscid, CLEA) to investigate the effects of
RSKi BI-D1870 in a shorter time scale to avoid liver toxicity. Carbo-
platin treatment (every 4 days, total of two doses; SelleckChem)
started on day 31 (15 mg/kg i.p. in sterile saline, N = 4). BI-D1870
was additionally administered on days 35–36 (25 mg/kg i.p. in 30%
PEG400 + 0.5% Tween80 + 5% Propylene glycol, N = 5). Control
group (N = 4) received injections of both vehicles. Mice were sacri-
ficed on day 36, 5 h after the second injection of RSKi.
In all experiments, housing was in individually ventilated cages
(IVC) with 4–5 mice per EU-standard sized cage with aspen-
bedding. Nest boxes and material were provided as enrichments.
Temperature was set to 20–24°C, relative humidity to 45–65%, and
light rhythm to 12 h. Welfare was checked daily by the animal facil-
ity personnel and/or the study-conducting researchers.
Immunofluorescence
For 2D immunofluorescence, cells grown on coverslips or in Nunc
Lab-Tek Chamber Slides (Sigma) were fixed with 4% PFA for 15 min
at RT, blocked with 5% BSA (Biowest) 0.1% Triton-X (Sigma) in PBS
for 30 min at RT and incubated with primary antibody in 5% BSA in
PBS for 1 h at RT. Cells were incubated with Alexa Fluor secondary
antibodies (Thermo Scientific) in 5% BSA in PBS for 30 min at RT
and mounted with VECTASHIELD Antifade Mounting Medium with
DAPI (Vector Laboratories). To improve nuclear PAX8 staining, cells
were post-fixed with ice-cold 1:1 mixture of acetone and methanol for
45 s before blocking.
For fixed 3D matrices, a 45 s post-fixation step with ice-cold 1:1
mixture of acetone and methanol was required. Matrices were then
blocked with blocking buffer (15% FBS – 0.3% Triton-X in PBS) for
2 h at RT and incubated with primary antibody in blocking buffer
overnight at 4°C. Multiple washing steps with 0.45% Triton-X in
PBS were performed during the following day, and matrices were
kept overnight at 4°C. Next, matrices were incubated with Alexa
Fluor secondary antibodies and phalloidin in blocking buffer for 4 h
at RT, washed several times with 0.45% Triton-X in PBS, and kept
overnight at 4°C. After washing with PBS for a day, matrices were
mounted on an object slide with VECTASHIELD Antifade Mounting
Medium with DAPI.
OVCAR4 xenograft tumors as well as HGSC patient tumors
embedded in Tissue-Tek OCT compound (Sakura Finetek) and
frozen were cut into 10-lm cryosections and stained as follows.
Sections were melt in ice-cold PBS for 10 min, fixed in ice-cold
acetone for 10 min, dried at RT for 10 min, washed with PBS, and
blocked with TNB blocking buffer [0.1 M Tris–HCl, pH 7.5; 0.15 M
NaCl; 0.5% (w/v) blocking reagent (PerkinElmer, Cat # FP1020)]
for 30 min at RT. Primary antibody incubation was performed
overnight at 4°C in a humidity chamber. After washes with TNT
(0.1 M Tris-Cl, pH 7.5; 0.15 M NaCl; 0.1% (v/v) Tween 20),
sections were incubated with Alexa Fluor secondary antibodies in
TNB for 40 min, washed with TNT, and rinsed with PBS. Slides
were mounted with VECTASHIELD Antifade Mounting Medium
with DAPI.
Confocal micrographs of immunofluorescence stainings were
obtained using a confocal microscope (LSM 780 and LSM 800) with
a C-Apochromat 40×, 1.2 NA water objective lens and with a Plan-
Apochromat 20×, 0.8 NA objective lens (all from Carl Zeiss).
Tissue microarray
All patients diagnosed between 2002 and 2006 in Stockholm
county with OC, fallopian tube, and primary peritoneal carcinoma
and undesignated primary site according to the Swedish cancer
registry were screened for eligibility. If not specified, all tumor
types are herein referred as OC. Inclusion criteria were age above
18 years, high-grade serous histology, FIGO stages IIC to IV, no
administration of chemotherapy prior to surgery or diagnostic
biopsy, and availability of tissue from the tumor sites. Exclusion
criteria were history of previous neoplastic disease (except for
in situ cancer or basalioma), diagnosis at autopsy, prior
chemotherapy, and not performed surgery or diagnostic biopsy. All
cases were re-classified by a gynecological pathologist from the
older three-tier differentiation grade to the new two-tier grade
system (Malpica et al, 2004), and only high-grade serous tumors
were selected.
Of the 401 screened for eligibility, 199 patients met the including
criteria, of which 32 did not have available tissue and 31 missed
histology data verification or clinical data; thus, 136 patients were
included in the study (Fig 9A, Appendix Table S1). Clinical data
were retrieved from the charts, coded, and collected in case report
files. The FIGO stage was classified according to the 1988 system
(Kandukuri & Rao, 2015). Response was defined according to
RECIST and CA-125 criteria (Rustin et al, 2011).
Formalin-fixed and paraffin-embedded (FFPE) tumor tissues
were retrieved from primary surgery or diagnostic biopsies derived
from the chemo-naı̈ve patients. A gynecological pathologist
reviewed the tumor sections stained with hematoxylin and eosin,
and representative areas of the tumor were chosen. Those were
punched, and cores of 1 mm diameter were placed in a receiver
TMA block. Two punches per patient were allowed, in line with the
rules for TMA building at the Department of Pathology at Karolinska
University Hospital; if possible, one punch was retrieved from the
primary site and one from the metastatic omentum or peritoneum.
Immunohistochemistry
Paraffin-embedded OVCAR4 xenograft tumors were cut into 7-lm-
thick slides and stained with Click-iTTM TUNEL Colorimetric IHC
Detection Kit (Thermo Scientific) and Ki67, following the manufac-
turer’s instructions or as follows. Sections were deparaffinized and
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rehydrated (3 × 5 min Tissue Clear, 3 × 2 min 99% ethanol,
2 × 2 min 95% ethanol, 1 × 2 min 70% ethanol, rinsed in water).
Antigen retrieval was performed using 10 mM sodium citrate pH 6
(8-min strong heat, 20-min medium heat, 20-min cooldown).
Endogenous peroxidase was quenched with 0.5% hydrogen perox-
ide for 30 min, 1 × 5 min water, and 1 × 5 min TBS. Sections were
blocked with 2.5% normal horse serum for 30 min (ImmPRESS,
Vector laboratories, Cat # MP-7402). Sections were incubated with
Ki67 antibody diluted in 2.5% normal horse serum overnight at 4°C
in a humidity chamber. Secondary antibody incubation was
performed with ImmPRESS reagent (anti-mouse IgG coupled to
peroxidase, ImmPRESS, Vector laboratories, Cat # MP-7402) for
30 min at RT. Staining was revealed using diaminobenzidine
substrate (5-min incubation, 5 min in water). Sections were coun-
terstained with aqueous hematoxylin (1-min incubation, rinsed with
water), dehydrated (1 × 2 min 70% ethanol, 1 × 5 min 95%
ethanol, 1 × 5 min 99% ethanol, 2 × 5 min Tissue Clear), and
mounted with Pertex (Histolab, Cat # 00811).
Tissue microarrays blocks were cut into 4-lm-thick slides and
stained for GPRC5A as described above with the following changes:
Secondary antibody was anti-rabbit IgG coupled to peroxidase
(ImmPRESS, Vector laboratories, Cat # MP-7401), incubation with
diaminobenzidine substrate lasted 3 min.
Olympus IX73 microscope and 3DHISTECH Pannoramic 250
FLASH II digital slide scanner were used for imaging.
TMA scoring
For the TMA scoring, a 4-point scale for GPRC5A-positive fraction
(0: < 10% of area stained, 1: 10–50%, 2: 50–80%, 3: 80–100%) and
maximum intensity of staining in cancer cells (0: negative; 1: mild;
2: moderate; and 3: strong) were used (Fig 9B; Liu et al, 2004;
Thomson et al, 2009). Two metrics were produced: GPRC5A-posi-
tive fraction of total tumor tissue and maximum intensity of marker-
positive area. For the survival analyses, GPRC5A maximum inten-
sity was dichotomized in low (scores 0–2) and high (score 3).
Twenty-five cores were reviewed separately by a second observer
(Pinder et al, 2013) with a scoring concordance of 0.353 (kappa test;
P = 0.006).
Image analyses and statistics
Quantitative assessment of immunoblots was performed using
Image Studio Lite, version 5.2. Quantification of IF signal intensity
and positive IF and IHC were performed with ImageJ and QuPath
(Bankhead et al, 2017).
All analyses were performed at least in triplicates, and the data
distribution was tested by Kolmogorov–Smirnov and Shapiro–Wilk
normality tests together with histogram analyses. Statistical signifi-
cance was determined using two-sided Student’s t-test and Mann–
Whitney U-test. P-values are depicted as *P < 0.05, **P < 0.01,
***P < 0.001.
For animal studies, the number of mice per treatment group
was limited to 4–6 to minimize the number of animals used yet
provide adequate statistical power. Mice were randomly assigned
into groups while simultaneously ensuring equal distribution of
tumor burden (based on bioluminescent signal) within each
group.
For the analyses of the TMA, OS was defined as survival from
date of diagnosis to date of death of any cause, in months. PFS was
defined as the time-frame from the date of diagnosis to recurrence or
death from any cause. ORR was defined as the proportion of patients
with reduction in tumor burden at the end of treatment (EOT)
measured according to the RECIST criteria: Cases with complete
regression or partial regression (CR, PR) were considered responsive,
while cases with stable disease or progressive disease (SD, PD) were
considered non-responsive. Platinum sensitivity (including platinum
alone or in combination with taxane) was defined according to the
disease-free time after EOT: sensitive (≥ 6 months disease-free),
refractory (recurrence during treatment), or resistant (PD, recurrence
< 6 months). In our analyses, refractory and resistant patients were
pooled in one group. All the metrics relative to GPRC5A showing a
significant P-value (< 0.05) at the univariate analysis (median age at
diagnosis, type of surgery, residual tumor after surgery) as well as
FIGO stage were entered into the multivariate model. Differences in
OS and PFS, according to the clinico-pathological variables of inter-
est, were estimated using logrank tests and Cox regression propor-
tional hazard models. Correlation analyses were performed through
Pearson chi-square test, gamma, and kappa tests. All TMA statistics
were performed in SPSS, version 24.0.
For the analysis of independent publicly available HGSC cohorts,
the TCGA dataset (N = 578, obtained through the TCGA data portal,
http://cancergenome.nih.gov/) and the GSE49997 dataset (N = 204
(Pils et al, 2012); retrieved from the Gene Expression Omnibus
The paper explained
Problem
Surgical removal of tumor masses and platinum chemotherapy are
the standard treatment for HCSC, which is often widely spread at the
time of diagnosis. Albeit initially effective in reducing tumor burden,
the cycles of platinum treatment induce changes in the surgically
inoperable treatment-escaping micro-metastases. These increasingly
resistant, residual cells give rise to incurable, recurrent disease. This
study assessed the long-neglected aspect of chemotherapy—the
potentially oncogenic rewiring of cancer cell signaling induced by the
platinum treatment per se as means to confer and sustain resistance.
Results
Using OC cell lines and patient-derived cultures, we have identified a
platinum-induced, adaptive resistance mechanism involving EphA2
and RSK1/2 kinases and GPRC5A receptor. Inhibition of the oncogenic
RSK-EphA2-pS897 signaling restored the tumor-suppressive EphA2-
pY588 and specially sensitized HGSC cells with high GPRC5A expres-
sion to platinum ex vivo. Histological analysis of GPRC5A in a TMA
with primary and metastatic HGSC specimens revealed its potential
as a predictive marker for patient survival and treatment response.
Impact
The herein identified mechanism on how platinum chemotherapy
induces an oncogenic RSK1/2-EphA2-GPRC5A signaling switch to
sustain residual resistant cells reveals a targetable vulnerability to
tackle them for complete tumor eradication. Importantly, this plat-
inum-induced signaling axis entails also a potential prognostic marker
for predicting survival and platinum treatment response: GPRC5A
marker expression in HGSC could be used to stratify the unresponsive
patients to combinatorial treatments targeting the oncogenic RSK-
EphA2-pS897 axis.
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database; Edgar et al, 2002) were used. For TCGA dataset, cases
that were healthy (N = 8), from different primary site than ovary/
fallopian tube (N = 4), low-grade (N = 87), or with no information
regarding histology or neoadjuvant chemotherapy (N = 48) were
excluded from the analysis. Differences in OS in 40% highest vs.
40% lowest GPRC5A expressing patients were estimated using
logrank test. This dataset was also used to investigate the correla-
tion of EphA2 and GPRC5A mRNA with Spearman’s rank test
(cBioPortal for Cancer Genomics). For GSE49997 dataset, cases that
were not of serous subtype (N = 33) or high-grade (N = 46) were
excluded from the analysis. Differences in OS and PFS in patients
with top 25% and low 25% EphA2, GPRC5A, RSK1-4 mRNA expres-
sion were estimated using logrank test. These statistics were
performed in SPSS, version 26.0.
Expanded View for this article is available online.
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